1. HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance
2. World Health Organization. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV. HIV treatment-interim guidance; 2018. Available from: http://apps.who.int/iris/bitstream/handle/10665/273632/WHO-CDS-HIV-18.18eng.pdf?ua=1.Accessed January 23, 2024.
3. World Health Organization. WHO recommends dolutegravir as preferred HIV treatment option in all populations; 2023. Available from: https://www.who.int/news/item/22-07-2019-who-recommends-dolutegravir-as-preferred-hiv-treatment-option-in-all-populations.Accessed. Accessed January 23, 2024.
4. World Health Organization. Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service, delivery and monitoring: recommendations for a public health approach; 2021. Available from: https://www.who.int/news/item/16-07-2021-who-publishes-new-consolidated-hiv-guidelines-for-prevention-treatment-service-delivery-monitoring. Accessed January 23, 2024.
5. AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial